Improved coronary vasodilatatory capacity by H.E.L.P. apheresis: Comparing initial and chronic treatment

Therapeutic Apheresis and Dialysis

Volumn 10, Issue 6, 2006, Pages 510-517

  Mellwig, Klaus P ^a   Van Buuren, Frank ^a   Schmidt, Henning K ^a   Wielepp, Peter ^a   Burchert, Wolfgang ^a   Horstkotte, Dieter ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Coronary vasodilatatory capacity; H.E.L.P. apheresis; Hypercholesterolemia; Positron emission tomography

Indexed keywords

ACETYLSALICYLIC ACID; AMMONIA N 13; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; COLESTIPOL; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; FENOFIBRATE; FIBRINOGEN; FLUINDOSTATIN; GLYCERYL TRINITRATE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; SIMVASTATIN;

ADULT; ANGIOCARDIOGRAPHY; APHERESIS; ARTICLE; BLOOD VISCOSITY; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; CORONARY VASCULAR RESISTANCE; DRUG DOSE SEQUENCE; DRUG EFFECT; FEMALE; HEART PERFUSION; HEPARIN INDUCED EXTRACORPOREAL LOW DENSITY LIPOPROTEIN PRECIPITATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MALE; PLASMA VISCOSITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; VASODILATION;

EID: 33845640550     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2006.00441.x     Document Type: Article

References (25)

1. Treasure CB, Klei JL, Weintraub WS et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
2. Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
3. Gould KL, Martucci JP, Goldberg DI et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 1994;89:1530-8.
4. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546-51.
5. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia and hypertension. J Clin Invest 1993;92:652-62.
6. Liao JK, Shin WS, Lee WY, et al. Oxidized low density lipoprotein decreases the the expression of endothelial nitric oxide synthase. J Biol Chem 1994;270:319-24.
7. Baller D, Notohamiprodjo G, Gleichmann U, Holzinger J, Weise R, Lehmann R. Improvement in coronary flow reserve determined by positron emission tomography after six months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999;99:2871-5.
8. Tsunekawa T, Hayashi T, Kano H et al. Cerivastatin, a hydroxymethyl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001;104:376-8.
9. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL-apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation 1997;95:76-82.
10. Hutchins G, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomography imaging. J Am Coll Cardiol 1990;15:1032-42.
11. Wieland H, Seidel D. A simple specific method for precipitation of low density lipoproteins. J Lip Res 1983;24:904-9.
12. Muzik O, Beanlands R, Hutchins GD, Mangner TJ, Nguyen N, Schwaiger M. Validation of nitrogen-13-ammonia tracer kinetic model for quantification of myocardial blood flow using PET. J Nucl Med 1993;34:83-91.
13. Bretschneider HJ, Frank A, Bernard U, Kochsiek K, Scheler F. Die Wirkung eines Pyrimidopyrimidin-Derivates auf die Sauerstoffversorgung des Herzmuskels. Arzneim Forsch 1959;9:49-59.
14. 2 supply by the DPTI/STTI ratio under maximal coronary dilation. Basic Res Cardiol 1979;74:378-88.
15. Baller D, Bretschneider HJ, Hellige G. A critical look at currently used indirect indices of myocardial oxygen consumption. Basic Res Cardiol 1981;76:163-81.
16. Brown BG, Zhao X-Q, Sacco DE, Albers J. Lipid Lowering and Plaque Regression. Circulation 1993;87:1781-91.
17. Hutchins GD, Schwaiger M, Wolfe E. Positron emission tomography to quantitative myocardial perfusion. Am J Card Imaging 1993;7:283-93.
18. Napoli C, Ambrosio G, Scarpato N et al. Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia. Am Heart J 1997;133:585-95.
19. Mellwig KP, Baller D, Gleichmann U et al. Improvement of coronary vasodilation capacity through single LDL-apheresis. Atherosclerosis 1998;139:173-8.
20. Holtz J, Krivokuca J, Allgeier RM, Goetz RM. Dipyridamol-recruitable coronary reserve is attenuated by suppression of nitric oxide synthesis in rats. Eur Heart J 1991;12:Abstact suppl 4,525.
21. Kleophas W, Leschke M, Tschope D et al. Akute Wirkung der extrakorporalen LDL-Cholesterin- und Fibrinogen-Elimination auf Blutrheologie und Mikrozirkulation. Dtsch Med Wschr 1990;115:3-7.
22. Schuff-Werner P. Untersuchungen zur hämorheologischen Wirksamkeit der LDL-Apherese: Habilitationsschrift am Fachbereich Medizin der Georg-August. Göttingen: Universität Göttingen, 1989.
23. Mancini GB, Henry GC, Macaya C et al. Angiotensin-converting Enzyme inhibition with Quinapril improves endothelial vasomotor Dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothlial Dysfunction) Study. Circulation 1996;94:258-68.
24. Leschke M, Schoebel FC, Mecklenbeck W et al. Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: a randomized dose-response trial. J Am Coll Cardiol 1996;27:575-84.
25. Schuff-Werner P, Schutz E, Seyde WC et al. Improved hemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL-precipitation (H.E.L.P.). Eur J Clin Invest 1989;19:30-7.